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Abstract
c-Myc oncogene is an important regulator of cell cycle and apoptosis, and its dysregulated
expression is associated with many malignancies. Myc is instrumental in directly or indirectly
regulating the progression through the G1 phase and G1/S transition, and transformation by Myc
results in perturbed cell cycle. Also contributory to the control of G1 is the Ras effector pathway
Raf/MEK/ERK MAP kinase. Together with GSK3, ERK plays an important role in the critical
hierarchical phosphorylation of S62/T58 controlling Myc protein levels. Therefore, our main aim
was to examine the levels of MAPK in Myc transformed cells in light of the roles of ERK in cell cycle
and control of Myc protein levels. We found that active forms of ERK were barely detectable in v-
Myc (MC29) transformed cells. Furthermore, we could only detect reduced levels of activated ERK
in c-Myc transformed cells compared to the non-transformed primary chick embryo fibroblast
cells. The addition of LiCl inhibited GSK3 and successfully restored the levels of ERK in v-Myc and
c-Myc transformed cells to those found in non-transformed cells. In addition, LiCl stabilised Myc
protein in the non-transformed and c-Myc transformed cells but not in v-Myc transformed cells.
These results can provide an important insight into the role of MAPK in the mechanism of Myc
induced transformation and carcinogenesis.
Background
The c-Myc oncogene is one of the most frequently dysreg-
ulated genes in human tumours. Myc was originally iden-
tified as the cellular homolog of the transforming part of
the viral isolate MC29 [1]. The c-Myc oncogene is a mem-
ber of the basic-helix-loop-helix-leucine-zipper transcrip-
tion (bHLH-ZIP) factors, which are essential for different
cellular processes [2]. Paradoxically, c-Myc promotes both
cell cycle progression and apoptosis under low serum con-
dition [3,4]. c-Myc regulates the cellular processes by con-
trolling a large number of target genes [5,6] through
heterodimerization with its biological partner Max [7-9].
The abundance of the Myc-Max heterodimer is effectively
controlled by the short lived Myc protein [10]. The Myc
protein is under tight and complex control mechanisms
[11].
Critical phosphorylation events determining the protein
half life occur in Myc homology box I (aa45-aa65) [10].
These detrimental events involve the hierarchical phos-
phorylation of S62 and T58 by ERK1/2 MAPK and GSK3β,
respectively [12]. It is widely accepted that these kinases
are involved in the phosphorylation events at these resi-
dues although other reports question the role of MAPK
[13]. These two kinases are part of two different Ras effec-
tor pathways. The presence of different Ras isoforms
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provides for selective activation of specific Ras effector
pathway, although this can only be shown in vivo [14]. It
has been reported that PI-3 kinase is most effectively acti-
vated by M-Ras and R-Ras and to a less extent by H-Ras
[15,16]. On the other hand, Raf-1 is most effectively acti-
vated by K-Ras [17,18]. This selective activation of differ-
ent Ras effector pathways has opposing effects on Myc
controlled functions. Whereas the activation of Raf fails to
suppress Myc induced apoptosis, the activation of PI-3
Kinase can effectively suppress it [19]. A key component
of the PI3-kinase/Akt (PKB) pro-survival pathway is GSK3
[20], whereas the active phosphorylated form of ERK1/2
MAPK is a downstream signal in the signalling cascade
Ras/Raf/MEK [21].
The ERK1/2 MAPK is one of three major MAPK signalling
pathways, which also includes JNK/SAPK and p38 kinase.
Constitutive activation of MEK/ERK has been reported in
cancer cells [22,23], with a possible role in cell transfor-
mation and oncogenesis [24]. The constitutive activation
of MAPK ERK1/2 could be linked to the mitogen inde-
pendence reported for oncogenes like Ras [25], Raf [26],
Jun [27] and Myc [4]. Therefore, one of the aims of this
study was to examine the status of active ERK2 in Myc
transformed chick embryo fibroblasts (CEF), the ideal
model for Myc induced transformation.
Our second aim was to examine the possibility of a cross
talk between ERK2 and GSK3 in Myc transformed fibrob-
lasts using LiCl to inhibit GSK3. Reports on signalling
between GSK3 and ERK1/2 are very scarce. Nonetheless, a
recent report has demonstrated that GSK3β was a natural
activator of the JNK/SAPK pathway [28]. Furthermore, it
has been demonstrated that GSK3β could be phosphor-
ylated on Ser9 and therefore inactivated by ERK1/2 medi-
ated pathways, mainly through p90rsk but also through a
novel mechanism downstream of ERK1/2 [29]. These
findings need to be verified in transformed phenotype.
Results and Discussion
We have found that v-Myc (MC29) transformed fibrob-
lasts have almost non-detectable active ERK2 (Figure 1A).
A control experiment using the SFCV vector without an
insert was performed in parallel with every experiment to
exclude any effect for the transfection procedure. Cells
transfected with the control vector gave identical results to
the non-transfected control CEF cells. The addition of 100
mM LiCl was very successful in restoring (not fully) the
levels of active ERK2 in v-Myc transformed fibroblasts to
those found in non-transformed fibroblasts within the
time scale of the experiment. The barely detectable basal
levels of phosphorylated ERK2 in v-Myc transformed
fibroblasts showed an increase after the addition of LiCl at
the earliest time point of 20 minutes (31% of basal levels
in non-transformed control CEF). These levels were
almost completely restored to the levels found in non-
transformed CEF after 80 minutes (83% of basal levels in
non-transformed control CEF).
On the other hand, c-Myc transformed fibroblasts have
shown attenuated but detectable active ERK2 levels com-
pared to the non-transformed CEF. The addition of 100
mM LiCl fully restored the levels of active ERK2 to those
found in non-transformed CEF (Figure 1B). The reduced
basal levels of ERK2 in c-Myc transformed fibroblasts
showed an increase at the earliest time point of 20 min-
utes (88% of basal levels in non-transformed control CEF)
after the addition of LiCl and were comparable to the lev-
els seen in the non-transformed CEF after 60 minutes. In
the non-transformed CEF, the addition of LiCl enhanced
the levels of active ERK2 considerably (Figure 1C). The
increase in the levels of active ERK2 in CEF after the addi-
tion of LiCl was detectable after 20 minutes (153% of
basal levels in non-transformed control CEF) and peaked
after 40 minutes (350% of basal levels in non-trans-
formed control CEF).
In addition, adding 100 mM of LiCl increased the levels of
inactive phosphorylated GSK3 α/β in a time dependent
manner (Figure 2) in agreement with the pattern seen for
the restored levels of active ERK2. We confirmed the acti-
vation of the pro-survival pathway PI3K signalling path-
way after the addition of LiCl by the inhibition of
apoptosis in Myc transformed fibroblasts (Figure 3).
Compared to the KCl control, LiCl treatment resulted in
2.1, 3.6 and 2.4 fold reduced apoptosis in v-Myc, c-Myc
and non-transformed control fibroblast cells, respectively.
The different cell populations showed variable number of
apoptotic cells after serum starvation. This is expected
since v-Myc is a stronger inducer of proliferation and
apoptosis than c-Myc [30,31]. Other researchers have also
demonstrated that inhibition of GSK3 using LiCl was con-
tributory to apoptosis inhibition[32]. Other GSK3 inhibi-
tors can be used to further support these findings.
Similar to what we have observed in our Myc transformed
cells, previous researchers have demonstrated that ERK1/
2 activity was repressed in c-Raf-1 (Raf22W), v-Ha-Ras,
and v-Src transformed cells by a single-specificity tyrosine
phosphatase [33]. A more recent report has also demon-
strated attenuated levels of ERK2 in v-Jun transformed
CEF cells, which was attributed to inefficient signalling
between Ras and Raf, and increased levels of MAPK phos-
phatase [34].
In light of the roles of ERK and GSK3 in Myc protein phos-
phorylation and stability, we investigated the effect of LiCl
addition on Myc protein half life in c-/v-Myc transformed
fibroblasts. Figures 4A and 4B show that the addition of
LiCl results in dramatic stabilisation of Myc in the non-Molecular Cancer 2005, 4:13 http://www.molecular-cancer.com/content/4/1/13
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The effect of LiCl on the levels of active ERK in Myc transformed and non transformed fibroblasts Figure 1
The effect of LiCl on the levels of active ERK in Myc transformed and non transformed fibroblasts. (A) A time 
course for the effect of LiCl on the levels of active ERK2 in v-Myc transformed fibroblasts (panel 1). Total ERK levels were not 
affected and were used as a loading control (panel 2). Panel 3 is a graphical representation of the ERK2 levels in Li+ and K+ 
treated v-Myc cells after normalisation to ERK2 levels in non-transformed control CEF (identical to CEF transfected with 
empty vector) growing under normal conditions. (B) A time course for the effect of LiCl on the levels of active ERK2 in c-Myc 
transformed fibroblasts (panel 1). Total ERK levels were not affected and were used as a loading control (panel 2). Panel 3 is a 
graphical representation of the ERK2 levels in Li+ and K+ treated c-Myc cells after normalisation to ERK2 levels in non-trans-
formed control CEF growing under normal conditions. (C) A time course for the effect of LiCl on the levels of active ERK2 in 
non-transformed control CEF (panel 1). Total ERK levels were not affected and were used as a loading control (panel 2). Panel 
3 is a graphical representation of the ERK2 levels in Li+ and K+ treated cells after normalisation to ERK2 levels in non-trans-
formed control CEF growing under normal conditions. The same pattern of expression was seen in several independent exper-
iments for all the panels.
Panel 1
Panel 2
A) Panel 3
Panel 3 B)
Panel 1
Panel 2
C)
Panel 3
Panel 1
Panel 2Molecular Cancer 2005, 4:13 http://www.molecular-cancer.com/content/4/1/13
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transformed and c-Myc transformed cells, respectively.
Surprisingly, although endogenous Myc is hardly detecta-
ble in non-transformed CEF (t1/2 < 1 minute), it was 30
fold more stable after the addition of LiCl (Figure 4A). We
verified this using immunoprecipitation (data not
shown). In comparison, c-Myc protein was 4 fold more
stable after LiCl treatment. Not surprisingly, both endog-
enous Myc in non-transformed control fibroblasts and
exogenously expressed Myc in c-Myc transformed fibrob-
lasts had similar half life values after the addition of LiCl
(30 and 32 minutes, respectively). However, LiCl failed to
further stabilise Myc in v-Myc transformed fibroblasts
(Figure 4C). Myc protein half life was 40 minutes com-
pared to 38 minutes in the control cells. Since MC29 v-
Myc has T58>M (T61>M in chicken), we did not expect
any effect for LiCl on Myc protein half life in these cells,
The effect of LiCl on the levels of GSK3 in non-transformed fibroblasts Figure 2
The effect of LiCl on the levels of GSK3 in non-transformed fibroblasts. (A) A western blot showing the levels of 
inactive or phosphorylated GSK3 α/β in non-transformed fibroblasts after the addition of Li+ or K+ salt control for the time 
points indicated. (B) A western blot showing the levels of phosphorylated and non-phosphorylated GSK3 α/β of the same 
samples in (A) above after stripping and re-probing of the blot with the appropriate antibody.Molecular Cancer 2005, 4:13 http://www.molecular-cancer.com/content/4/1/13
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The effect of LiCl on the apoptosis levels of serum starved Myc transformed and non-transformed fibroblasts Figure 3
The effect of LiCl on the apoptosis levels of serum starved Myc transformed and non-transformed fibroblasts. 
(A) A graphical representation of the percentage of apoptotic v/c-Myc transformed and non transformed fibroblasts 17 hours 
after serum deprivation and addition of Li+ or K+. The error bars are the standard error of three independent experiments. 
The total number of cells counted for each experiment was 50 cells. (B) &(C) Representative sections of Hoeschst 33258 
stained c-Myc cells after K+ and Li+ treatment, respectively.Molecular Cancer 2005, 4:13 http://www.molecular-cancer.com/content/4/1/13
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Myc protein turnover after the addition of LiCl in Myc transformed and non transformed fibroblasts Figure 4
Myc protein turnover after the addition of LiCl in Myc transformed and non transformed fibroblasts. (A) Endog-
enous Myc protein in Li+ and K+ treated non-transformed fibroblasts. This was identical to fibroblasts transfected with empty 
vector. Panel 1 is the scanned image of a western blot autoradiograph. Panel 2 shows the half life values of the Myc protein 
under the different conditions. CEF represents the non-transformed control fibroblasts (B) Turnover of the Myc protein in Li+ 
and K+ treated c-Myc transformed fibroblasts. Panel 1 is the scanned image of a western blot autoradiograph. Panel 2 shows 
the half life values of the Myc protein under the different conditions. CEF represents the non-transformed control fibroblasts 
(C) Turnover of the Myc protein in Li+ and K+ treated v-Myc transformed fibroblasts. Panel 1 is the scanned image of a western 
blot autoradiograph. Panel 2 shows the half life values of the Myc protein under the different conditions. CEF represents the 
non-transformed control fibroblasts. The experiments were independently repeated three times and one representative 
experiment is shown.Molecular Cancer 2005, 4:13 http://www.molecular-cancer.com/content/4/1/13
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although it was a necessary control. Other researchers doc-
umented a small effect for LiCl on Myc stability (2 fold) in
immortalised cell lines [35]..
We can conclude that LiCl has direct effects on the hierar-
chical phosphorylation of S62 and T58 (S65 and T61 in
chicken) by controlling the levels of active ERK2 and
GSK3, respectively. The results in this study show that this
is important for the Myc half life in the non-transformed
and c-Myc transformed fibroblasts but not in the v-Myc
transformed cells. In this context, other researchers have
found that S62 phosphorylation was necessary for Myc
stabilization following Ras activation or serum
stimulation[36].
Conclusion
In this short communication we provided important find-
ings about Myc induced transformation. The abrogation
of active MAPK in Myc transformed cells can potentially
provide an insight into the mechanism of Myc induced
transformation. Clarification of the mechanism of ERK2
inactivation in Myc transformed CEF is needed. Further-
more, it is critical to examine the implications of the dif-
ferences in active ERK2 levels between v-Myc and c-Myc
transformed cells and the possible role this has in Myc
induced transformation and protein stability. Last, we
need to elucidate on the possibility of a cross-talk between
GSK3 and ERK, as this could be a very important mecha-
nism for controlling the Myc protein.
Methods
Cell Culture, Transfection and Inhibition Studies
Cell culture and transfection of the appropriate SFCV-Myc
construct (10 µg) together with RCAN(A) helper (4 µg)
into secondary CEF were performed as described previ-
ously [37]. A control experiment using the SFCV vector
without an insert was used with every experiment as a
transfection control. After G418 Neomycin selection
(BDH, UK), cultures were expanded and used for the
subsequent studies. At this stage, cells transfected with
vectors containing either c-Myc or v-Myc were fully trans-
formed as determined by anchorage independent growth
and visible transformation characteristics, such as meta-
morphosis (data not shown). LiCl was added for 30 min-
utes at a final concentration of 100 mM to exponentially
growing CEF, c-Myc or v-Myc cells before harvesting for
western blotting. KCl was used in all the experiments as a
salt control. For the Myc protein turnover studies, a pro-
tein synthesis inhibitor (emetine from Sigma, UK) was
added 30 minute after the addition of either LiCl or KCL
at a final concentration of 0.1 mM [38] for the indicated
times shown in the figure.
Apoptosis Induction and Measurement
Apoptosis was induced by incubating the cells in a
medium containing 0.2% serum for 17 hours. Serum star-
vation for longer periods of time resulted in apoptosis in
almost all of the v-Myc cell population. To measure the
percentage of the apoptotic cells, the cell population was
divided into adherent and suspended cells. The adherent
cells were trypsinised, washed in 1× phosphate buffered
saline (PBS) and fixated in ice cold 3:1 glacial acetic acid/
methanol solution. Then, the cells were permealised at
room temperature using a solution of 1× PBS/0.1% triton
X-100 for 5 minutes. The cells were then stained in a solu-
tion of 2.5 µg/µl Hoeschst 33258 (Sigma, UK) in 1× PBS/
0.1 % triton X-100 on ice and protected from light. After
that, the cells were washed twice in 1× PBS/0.1% triton X-
100, made adherent onto a slide using a cytospin, and
viewed and counted under an epi-fluorescent microscope
using a DAPI filter. We treated the suspended cells in
exactly the same way with the exception that they did not
need trypsinisation. To calculate the total number of
apoptotic cells in both adherent and suspended cells, we
used the following formula:
SDS PAGE Western Blotting and Protein Half Life 
Measurement
Cell lysates were prepared by lysing cultures in SDS-sam-
ple buffer containing 1% SDS without bromophenol blue
or mercaptoethanol. Protein concentration was measured
using Micro BCA reagent (Pierce, UK) before loading onto
7.5% SDS-PAGE gels. Transfer to nitrocellulose and west-
ern blotting was performed essentially as described previ-
ously [37], except that incubation with the primary
antibody was performed in 2.5% BSA in TBS-Tween20 for
ERK western blots. Active phosphorylated ERK was
detected using rabbit polyclonal antibodies (catalogue
number 9101, New England Biolabs, UK) and total phos-
phorylated and non-phosphorylated ERK levels were
detected using rabbit polyclonal antibody (catalogue
number 71–1800, Zymed, UK). Inactive phosphorylated
GSK3 α/β (Ser21/9) protein was detected using a rabbit
polyclonal antibody (catalogue number 9331S, Cell Sign-
aling Technology, UK) and phosphorylated and non-
phosphorylated GSK3 α/β levels were detected using a
rabbit polyclonal antibody raised against GSK3 β but
detected both GSK3 α and β (catalogue number 9332,
Cell Signaling Technology, UK). Full length Myc protein
was expressed in our laboratory and was used to raise rab-
bit polyclonal antibodies against. To re-probe a blot, it
was first submerged in a solution containing 100 mM 2-
mercaptoethanol, 2% SDS and 62.5 mM Tris HCl pH 6.7
at 50°C for 1 hour, with agitation. Then, the blot was
washed in a solution containing TBS/0.1% Tween20 for
10 minutes three times at room temperature. Last, the blot
(
Apoptotic cells counted
Total cells counted
Adherent Cell
⋅⋅ ⋅
⋅⋅
×⋅ ⋅⋅ +
⋅⋅ ⋅
⋅⋅
× Number
Apoptotic cells counted
Total cells counted
Sus )( p pended Cell Number
Adherent Cell Number Suspended Cell Nu
⋅⋅
⋅⋅ + ⋅⋅
)
m mberMolecular Cancer 2005, 4:13 http://www.molecular-cancer.com/content/4/1/13
Page 8 of 8
(page number not for citation purposes)
was blocked and probed as above with the appropriate
antibody. Equal loading of lanes was determined by stain-
ing the polyacrylamide gel after transfer onto a nitrocellu-
lose membrane in coomassie blue solution for 2 hours
(50% methanol, 10% acetic acid, 0.25% coomassie blue
R-250) and de-staining in a solution containing 10%
methanol and 5% acetic acid for 4 hours. The different
band intensities were analysed using the Kodak 1D image
analysis software and then they were plotted on a linear
graph for the ERK levels. For the calculation of the Myc
protein half life, the densitometric values were plotted on
a semi-logarithmic graph against time and then fitted to
an exponential line. The half life of the protein was calcu-
lated from the equation:
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